What are the efficacy and functions of adagrasib?

Adagrasib (Adagrasib is an investigational, highly selective, oral, small molecule KRAS G12C inhibitor optimized to sustain targeted therapy, a property important for the treatment of KRAS G12C mutant cancers that regenerate every 24-48 hours. Research on adagrasib shows that the drug has a long half-life, broad tissue distribution and good tolerability. Adagrasiib has shown single-agent efficacy in non-small cell lung cancer, colorectal cancer, pancreatic cancer and other solid tumors with KRASG12C mutations, and has also been used in combination with other anti-tumor therapies in patients with advanced solid tumors in some clinical studies.

Adagrasib is a drug that targets mutantKRAS oncogene and is currently approved and widely used to treat patients with non-small cell lung cancer. KRAS gene mutations are one of the most common mutations in common human cancers, accounting for approximately 15% to 30% of all cancer mutations. Adagrasiib exerts its efficacy and effect by inhibiting the signaling pathway activated by mutant KRAS protein. Adagrasiib can be customized according to the patient's specific genetic mutations, improving the accuracy and effectiveness of personalized treatment.

Adagrasib inhibits the growth and proliferation of tumor cells by blocking the activation signaling pathway of mutantKRAS protein. It can interfere with the normal functions of cancer cells, causing them to die or stop multiplying. Adagrasib can also reduce the metastasis ability of cancer cells and prevent cancer from spreading to other tissues and organs in the body. Compared with traditional treatment methods, adagrasib can maintain stable drug concentrations in the body for a long time, thereby improving efficacy and duration and reducing the frequency of treatment. Adagrasiib has mild side effects and can improve patients' quality of life.